Filing Details
- Accession Number:
- 0001103021-20-000032
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-04 19:31:59
- Reporting Period:
- 2020-01-31
- Accepted Time:
- 2020-02-04 19:31:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1103021 | Biodelivery Sciences International Inc | BDSI | Pharmaceutical Preparations (2834) | 352089858 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1748462 | B Thomas Smith | C/O Biodelivery Sciences Intl, Inc., 4131 Parklake Ave. Suite 225 Raleigh NC 27612 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-01-31 | 7,666 | $0.00 | 7,666 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-01-31 | 2,927 | $5.38 | 4,739 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2020-01-31 | 7,666 | $0.00 | 7,666 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
15,334 | 2022-01-31 | No | 4 | M | Direct |
Footnotes
- The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest equally on January 31, 2021 and January 31, 2022.
- The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan to cover the Reporting Person's tax liability upon the vesting of the RSUs.
- On January 31, 2019, the Reporting Person sold an aggregate of 2,927 shares of the Issuer's Common Stock at a weighted average price of $5.38 per share. The highest sale price for the Common Stock was $5.40 per share and the lowest sale price was $5.36 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.